Pharmacological Reviews
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     


0031-6997/07/5902-185-205$7.00
Pharmacol Rev 59:185-205, 2007

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Erratum
Right arrow An erratum has been published
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ribatti, D.
Right arrow Articles by Nussdorfer, G. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ribatti, D.
Right arrow Articles by Nussdorfer, G. G.

Nonclassic Endogenous Novel Regulators of Angiogenesis

Domenico Ribatti, Maria Teresa Conconi and Gastone G. Nussdorfer

Department of Human Anatomy and Histology, School of Medicine, University of Bari, Bari, Italy (D.R.); Departments of Pharmaceutical Sciences, School of Pharmacy (M.T.C.) and Human Anatomy and Physiology (G.G.N.), School of Medicine, University of Padua, Padua, Italy

Abstract
I. Introduction
II. Classic Mechanisms of Angiogenesis Regulation
    A. General Overview
    B. The Angiogenic Switch
        1. Genetic Factors.
        2. Secretion of Growth Factors.
        3. Recruitment of Inflammatory Cells Releasing Angiogenic Factors.
        4. Mobilization of Angiogenic Cytokines from Extracellular Matrix.
        5. Interactions of Adhesion Receptors with Matrix Metalloproteinase-2.
        6. Classic Endogenous Inhibitors of Angiogenesis (Table 1).
        7. The Validity of in Vitro and in Vivo Assays as Predictors of Effects on Angiogenesis Relevant to Physiology and Pathophysiology.
    C. Tumor Angiogenesis
III. Nonclassic Endogenous Stimulators of Angiogenesis
    A. Erythropoietin
    B. Angiotensin II
    C. Endothelins
    D. Proadrenomedullin-Derived Peptides
        1. Adrenomedullin.
        2. Proadrenomedullin N-Terminal 20 Peptide.
    E. Urotensin-II
    F. Adipokines
        1. Leptin.
        2. Adiponectin.
        3. Resistin.
    G. Neuropeptide-Y
    H. Vasoactive Intestinal Peptide and Pituitary Adenylate Cyclase-Activating Polypeptide
    I. Substance P
    J. Summary
IV. Nonclassic Endogenous Inhibitors of Angiogenesis
    A. Somatostatin
    B. Ghrelin
    C. Natriuretic Peptides
    D. Summary
V. Conclusions and Perspectives
Angiogenesis, the process through which new blood vessels arise from preexisting ones, is regulated by several "classic" factors, among which the most studied are vascular endothelial growth factor (VEGF) and fibroblast growth factor-2 (FGF-2). In recent years, investigations showed that, in addition to the classic factors, numerous endogenous peptides play a relevant regulatory role in angiogenesis. Such regulatory peptides, each of which exerts well-known specific biological activities, are present, along with their receptors, in the blood vessels and may take part in the control of the "angiogenic switch." An in vivo and in vitro proangiogenic effect has been demonstrated for erythropoietin, angiotensin II (ANG-II), endothelins (ETs), adrenomedullin (AM), proadrenomedullin N-terminal 20 peptide (PAMP), urotensin-II, leptin, adiponectin, resistin, neuropeptide-Y, vasoactive intestinal peptide (VIP), pituitary adenylate cyclase-activating polypeptide (PACAP), and substance P. There is evidence that the angiogenic action of some of these peptides is at least partly mediated by their stimulating effect on VEGF (ANG-II, ETs, PAMP, resistin, VIP and PACAP) and/or FGF-2 systems (PAMP and leptin). AM raises the expression of VEGF in endothelial cells, but VEGF blockade does not affect the proangiogenic action of AM. Other endogenous peptides have been reported to exert an in vivo and in vitro antiangiogenic action. These include somatostatin and natriuretic peptides, which suppress the VEGF system, and ghrelin, that antagonizes FGF-2 effects. Investigations on "nonclassic" regulators of angiogenesis could open new perspectives in the therapy of diseases coupled to dysregulation of angiogenesis.

Address correspondence to: Dr. Domenico Ribatti, Department of Human Anatomy and Histology, Piazza Giulio Cesare 11, I-79124 Bari, Italy. E-mail: ribatti{at}anatomia.uniba.it




This article has been cited by other articles:


Home page
 J ANIM SCIHome page
J. A. Grado-Ahuir, P. Y. Aad, G. Ranzenigo, F. Caloni, F. Cremonesi, and L. J. Spicer
Microarray analysis of insulin-like growth factor-I-induced changes in messenger ribonucleic acid expression in cultured porcine granulosa cells: Possible role of insulin-like growth factor-I in angiogenesis
J Anim Sci, June 1, 2009; 87(6): 1921 - 1933.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
E. I. Ager, J. Neo, and C. Christophi
The renin-angiotensin system and malignancy
Carcinogenesis, September 1, 2008; 29(9): 1675 - 1684.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition
Copyright © 2007 by the American Society for Pharmacology and Experimental Therapeutics